Cargando…

CuATSM effectively ameliorates ALS patient astrocyte‐mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis

Patient diversity and unknown disease cause are major challenges for drug development and clinical trial design for amyotrophic lateral sclerosis (ALS). Transgenic animal models do not adequately reflect the heterogeneity of ALS. Direct reprogramming of patient fibroblasts to neuronal progenitor cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dennys, Cassandra N., Roussel, Florence, Rodrigo, Rochelle, Zhang, Xiaojin, Sierra Delgado, Andrea, Hartlaub, Annalisa, Saelim‐Ector, Asya, Ray, Will, Heintzman, Sarah, Fox, Ashley, Kolb, Stephen J., Beckman, Joseph, Franco, Maria Clara, Meyer, Kathrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092379/ https://www.ncbi.nlm.nih.gov/pubmed/36213964 http://dx.doi.org/10.1002/glia.24278

Ejemplares similares

CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
por: Vieira, Fernando G., et al.
Publicado: (2017)

Monte Carlo Evaluation of Dose Enhancement Due to CuATSM or GNP Uptake in Hypoxic Environments with External Beam Radiation
por: Martinez, Stephen, et al.
Publicado: (2020)

EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes
por: Dennys, Cassandra, et al.
Publicado: (2022)

CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1(G93A) mice with a C57BL/6 background
por: Lum, Jeremy S., et al.
Publicado: (2021)

Cu(II)(atsm) Attenuates Neuroinflammation
por: Choo, Xin Yi, et al.
Publicado: (2018)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

Cellular Uptake of the ATSM−Cu(II) Complex under Hypoxic Conditions
por: Walke, Gulshan R., et al.
Publicado: (2021)

Does the ATSM-Cu(II) Biomarker Integrate into the Human Cellular Copper Cycle?
por: Walke, Gulshan R., et al.
Publicado: (2019)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study
por: Clausen, Malene Martini, et al.
Publicado: (2014)

Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
por: Li, Fan, et al.
Publicado: (2015)

Assessment of the Tumor Redox Status in Head and Neck Cancer by (62)Cu-ATSM PET
por: Tsujikawa, Tetsuya, et al.
Publicado: (2016)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM)
por: Shaughnessy, Fiona, et al.
Publicado: (2014)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
por: Gangemi, Vincenzo, et al.
Publicado: (2019)

Validation of (64)Cu-ATSM damaging DNA via high-LET Auger electron emission
por: McMillan, Dayton D., et al.
Publicado: (2015)

(64)Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
por: Nachankar, Ankita, et al.
Publicado: (2021)

Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia
por: Sanghera, Bal, et al.
Publicado: (2016)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model
por: Park, Seong Yong, et al.
Publicado: (2015)

Cu(II)(atsm) improves the neurological phenotype and survival of SOD1(G93A) mice and selectively increases enzymatically active SOD1 in the spinal cord
por: Hilton, James B., et al.
Publicado: (2017)

Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [(64)Cu][Cu(ATSM)] PET and proteomic studies
por: Fantin, Jade, et al.
Publicado: (2023)

Cerebral Oxidative Stress in Early Alzheimer’s Disease Evaluated by (64)Cu-ATSM PET/MRI: A Preliminary Study
por: Okazawa, Hidehiko, et al.
Publicado: (2022)

The hypoxia imaging agent Cu(II)(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
por: Hung, Lin W., et al.
Publicado: (2012)

Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm)
por: Cheng, Lesley, et al.
Publicado: (2016)

(64)Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Multiple Administrations of (64)Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Cardioprotective effects of Cu((II))ATSM in human vascular smooth muscle cells and cardiomyocytes mediated by Nrf2 and DJ-1
por: Srivastava, Salil, et al.
Publicado: (2016)

Preclinical Pharmacokinetic and Safety Studies of Copper-Diacetyl-Bis(N(4)-Methylthiosemicarbazone) (Cu-ATSM): Translational Studies for Internal Radiotherapy
por: Matsumoto, Hiroki, et al.
Publicado: (2019)

Feasibility of Renal Blood Flow Measurement Using (64)Cu-ATSM PET/MRI: A Quantitative PET and MRI Study
por: Nishikawa, Yudai, et al.
Publicado: (2023)

Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice
por: Pyun, Jae, et al.
Publicado: (2023)

Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography
por: Ballegeer, Elizabeth A, et al.
Publicado: (2013)

ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL
por: Yoshii, Yukie, et al.
Publicado: (2022)

Controlled Administration of Penicillamine Reduces Radiation Exposure in Critical Organs during (64)Cu-ATSM Internal Radiotherapy: A Novel Strategy for Liver Protection
por: Yoshii, Yukie, et al.
Publicado: (2014)

Micro Regional Heterogeneity of (64)Cu-ATSM and (18)F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis
por: Zornhagen, Kamilla Westarp, et al.
Publicado: (2015)

Neurotoxic Astrocytes Directly Converted from Sporadic and Familial ALS Patient Fibroblasts Reveal Signature Diversities and miR-146a Theragnostic Potential in Specific Subtypes
por: Gomes, Cátia, et al.
Publicado: (2022)

Extracellular ATP and the P2X(7 )receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis
por: Gandelman, Mandi, et al.
Publicado: (2010)

Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond
por: Nikseresht, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jmssmdmcj4fes7h78ibjdoj8g5